Teva Pharmaceutical Industries Limited (TEVA)

Teva Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	16,776	16,544	15,846	14,925	15,878	16,659
Revenue Growth (YoY)	0.02%	4.41%	6.17%	-6.00%	-4.69%	-1.35%
Cost of Revenue	8,373	8,481	8,200	7,952	8,284	8,933
Gross Profit	8,403	8,063	7,646	6,973	7,594	7,726
Selling, General & Admin	3,805	3,702	3,498	3,445	3,528	3,671
Research & Development	993	998	953	838	967	997
Other Operating Expenses	45	-9	15	28	20	3
Operating Expenses	4,843	4,691	4,466	4,311	4,515	4,671
Operating Income	3,560	3,372	3,180	2,662	3,079	3,055
Interest Expense	-955	-1,002	-1,029	-930	-891	-901
Interest & Investment Income	86	86	68	10	-	104
Earnings From Equity Investments	4	1	2	21	9	138
Currency Exchange Gain (Loss)	-58	-17	-30	16	-7	26
Other Non Operating Income (Expenses)	-6	-48	-66	-62	-69	-63
EBT Excluding Unusual Items	2,631	2,392	2,125	1,717	2,121	2,359
Merger & Restructuring Charges	-218	-74	-111	-146	-133	-120
Impairment of Goodwill	-280	-1,280	-700	-2,045	-	-4,628
Gain (Loss) on Sale of Investments	-	-	-	-	-90	-
Gain (Loss) on Sale of Assets	17	17	28	64	58	19
Asset Writedown	-772	-1,275	-378	-402	-584	-1,918
Legal Settlements	-434	-760	-1,038	-2,069	-698	-60
Other Unusual Items	-44	-303	-548	-261	-7	81
Pretax Income	900	-1,283	-622	-3,142	667	-4,267
Income Tax Expense	238	676	-7	-643	211	-168
Earnings From Continuing Operations	662	-1,959	-615	-2,499	456	-4,099
Minority Interest in Earnings	51	320	56	53	-39	109
Net Income	713	-1,639	-559	-2,446	417	-3,990
Net Income to Common	713	-1,639	-559	-2,446	417	-3,990
Shares Outstanding (Basic)	1,142	1,131	1,119	1,110	1,102	1,095
Shares Outstanding (Diluted)	1,154	1,131	1,119	1,110	1,107	1,095
Shares Change (YoY)	2.33%	1.07%	0.81%	0.27%	1.10%	0.37%
EPS (Basic)	0.62	-1.45	-0.50	-2.20	0.38	-3.64
EPS (Diluted)	0.62	-1.45	-0.50	-2.20	0.38	-3.64
Free Cash Flow	578	749	842	1,042	236	638
Free Cash Flow Per Share	0.50	0.66	0.75	0.94	0.21	0.58
Gross Margin	50.09%	48.74%	48.25%	46.72%	47.83%	46.38%
Operating Margin	21.22%	20.38%	20.07%	17.84%	19.39%	18.34%
Profit Margin	4.25%	-9.91%	-3.53%	-16.39%	2.63%	-23.95%
Free Cash Flow Margin	3.45%	4.53%	5.31%	6.98%	1.49%	3.83%
EBITDA	4,571	4,431	4,333	3,970	4,409	4,612
EBITDA Margin	27.25%	26.78%	27.34%	26.60%	27.77%	27.68%
D&A For EBITDA	1,011	1,059	1,153	1,308	1,330	1,557
EBIT	3,560	3,372	3,180	2,662	3,079	3,055
EBIT Margin	21.22%	20.38%	20.07%	17.84%	19.39%	18.34%
Effective Tax Rate	26.44%	-	-	-	31.63%	-
Advertising Expenses	-	-	-	-	246	225

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q